Related Experiment Video

Updated: Oct 1, 2025

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.4K

PTPIP51 inhibits non-small-cell lung cancer by promoting PTEN-mediated EGFR degradation

Minwei He1, Xing Wang2, Wei Chen3

  • 1Department of Immunology, School of Basic Medical Sciences, Peking University Health Science Center, Key Laboratory of Medical Immunology of the Ministry of Public Health, Beijing, China; Institute of Health Service and Transfusion Medicine, Beijing, 100850, P. R. China.

Life Sciences
|March 3, 2022
PubMed

Insights

Protein tyrosine phosphatase interacting protein 51 (PTPIP51) is downregulated in non-small cell lung cancer (NSCLC). Its restoration suppresses tumor growth by inhibiting EGFR signaling and promoting cancer cell death.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Protein tyrosine phosphatase interacting protein 51 (PTPIP51) is implicated in cellular signaling pathways.
  • Dysregulation of PTPIP51 has been observed in various cancers.
  • Understanding PTPIP51's role in non-small cell lung cancer (NSCLC) is crucial for therapeutic development.

Purpose of the Study:

  • To investigate the role of PTPIP51 in non-small cell lung cancer (NSCLC).
  • To elucidate the molecular mechanisms underlying PTPIP51's function in NSCLC.
  • To evaluate the therapeutic potential of PTPIP51 in combination with EGFR inhibitors.

Main Methods:

  • Western blotting and immunohistochemistry to assess PTPIP51 expression in NSCLC tissues.
  • Cellular assays to analyze the impact of PTPIP51 overexpression on EGFR signaling pathways (PI3K/Akt, RAS/RAF/ERK, JAK/STAT3).
  • In vitro and in vivo experiments to evaluate the combined efficacy of PTPIP51 and gefitinib.

Main Results:

  • PTPIP51 expression is downregulated in NSCLC, and its higher levels correlate with better patient outcomes.
  • PTPIP51 overexpression inhibits key oncogenic signaling pathways, including EGFR, PI3K/Akt, RAS/RAF/ERK, and JAK/STAT3.
  • PTPIP51 forms a complex with PTEN, enhancing PTEN phosphorylation and promoting EGFR ubiquitylation and lysosomal degradation.
  • Combined treatment with PTPIP51 and gefitinib synergistically inhibits NSCLC growth and induces apoptosis.

Conclusions:

  • PTPIP51 functions as a tumor suppressor in NSCLC.
  • PTPIP51 exerts its tumor-suppressive effects by modulating PTEN phosphorylation and facilitating EGFR degradation.
  • PTPIP51 holds promise as a therapeutic target and a sensitizer for EGFR inhibitor therapy in NSCLC.
Keywords:
EGFRNSCLCPTENPTPIP51

More Related Videos

The Soft Agar Colony Formation Assay08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

112.4K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K